# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC's Chris McCarthy discusses biotech investor sentiment at the RBC Global Healthcare Conference. Focused on upcoming bina...
Truist Securities analyst Asthika Goonewardene maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $19 pric...
HC Wainwright & Co. analyst Robert Burns reiterates Caribou Biosciences (NASDAQ:CRBU) with a Buy and maintains $24 price...
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of...
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announ...
Caribou Biosciences, Inc. (NASDAQ:CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announ...
U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Friday.
-- FDA has cleared Caribou's IND application for CB-010 in lupus nephritis and extrarenal lupus; GALLOP Phase 1 clinical tr...